FDA Recalls Blood Pressure Drugs Due To Cancer Risks
The FDA issued a voluntary recall of a number of drugs that are used to help control blood pressure. The drugs contain an active ingredient called valsartan, which contains an impurity, N-nitrosodimethylamine (NDMA), that’s now been linked to cancer. NDMA is considered a “probable carcinogen.”
Not all NDMA products are being pulled from shelves, however, it seems the determining factor is the amount of NDMA contained.
“The FDA is committed to maintaining our gold standard for safety and efficacy. That includes our efforts to ensure the quality of drugs and the safe manner in which they’re manufactured,” said FDA Commissioner Scott Gottlieb, M.D. “When we identify lapses in the quality of drugs and problems with their manufacturing that have the potential to create risks to patients, we’re committed to taking swift action to alert the public and help facilitate the removal of the products from the market. As we seek the removal of certain drug products today, our drug shortages team is also working hard to ensure patients’ therapeutic needs are met in the United States with an adequate supply of unaffected medications.”
Here are the recalled products:
|Valsartan||Teva Pharmaceuticals Industries Ltd.|
|Valsartan/Hydrochlorothiazide (HCTZ)||Solco Healthcare|
|Valsartan/Hydrochlorothiazide (HCTZ)||Teva Pharmaceuticals Industries Ltd.|
“We have carefully assessed the valsartan-containing medications sold in the United States, and we’ve found that the valsartan sold by these specific companies does not meet our safety standards. This is why we’ve asked these companies to take immediate action to protect patients,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research, via WSVN.
Author: Jim Satney
PrepForThat’s Editor and lead writer for political, survival, and weather categories.
*As an Amazon Associate I earn from qualifying purchases
Like Us On Facebook -